Abstract
Thyroglobulin (Tg) antibodies (TgAb) screening is recommended in patients with differentiated thyroid carcinoma (DTC) to validate Tg measurements. We compared a new multiplexed and 2 conventional TgAb immunoassays in patients with DTC and healthy controls. TgAb were measured by 2 conventional automated immunoassays and a multiplexed immunoassay in sera from 163 patients with DTC and 64 controls. No significant differences were found between the different assays when the suggested manufacturer cutoffs were used. The positive rate of multiplexed assay, but not of conventional assays, significantly increased when limits of detection were used as cutoff. Further technical evaluations are necessary to explain the very high rate of detectable TgAb values in both patients with DTC and controls by the multiplexed assay. For the moment, we suggest caution in using such methods in the current clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
